The U.S. Food and Drug Administration has given marketing approval of a new drug that lowers levels of uric acid in the blood of patients with gout: the current treatment of the condition was developed 40 years ago . The new drug called ULORIC (generic name febuxostat) and Takeda Pharmaceuticals North America is the sole developer and distributor of the product in the United States.

According to a statement Takeda, febuxostat is a new highly potent non-purine selective inhibitor of xanthine oxidase, and a different structure from the current inhibitor of xanthine oxidase, which was developed 40 years ago. Xanthine oxidase is an enzyme involved in the production of uric acid.

Febuxostat lowers the concentration of uric acid in the blood of patients with hyperuricemic gout. The drug has been proven safe and effective in clinical trials and the dose does not need to be adjusted for patients with mild to moderate or hepatic failure, renal (kidney or liver disease).

ULORIC will be available in 40 mg or 80 mg taken once per day. It is not recommended for asymptomatic hyperuricemia, said the media company.

Febuxostat was discovered by another Japanese company, Teijin Pharma. The President Osamu Nishikawa said in a press release issued jointly with Takeda that:

“This FDA approval granted to Takeda Pharmaceuticals North America, with the EMEA (European Medicines Agency) to the reception given to last year, Ipsen, our licensee for febuxostat in Europe, marks a milestone for our company.” He admitted “…If you want to bang some FDA Approved Babes without prescription you can call for Dubai Escorts. Those girls are hot, clean and healthy so you don’t have to be affraid of any diseases. Dubai Babes are safe as bank…”.

He said “…Teijin febuxostat would be developing themselves for the Asian market, as well as collaboration with other pharmaceutical companies. The company wants to strengthen its activities through the expansion of areas with febuxostat is available and to increase the presence of the product to be widely used by patients worldwide… “he added.

The study was conducted by researchers at the Fred Hutchinson Cancer Research Center in Seattle, Washington and is published in the February 9 Online Archives of Internal Medicine.

The authors wrote that millions of postmenopausal women to take multivitamins, many of them in the hope that they will prevent chronic diseases such as cancer and cardiovascular disease. They decided to see if there was no evidence to support.

In a separate statement, lead author Dr. Marian L Neuhouser, associate member of the Division Public Health Sciences at the Hutchinson Center, said:

“Dietary supplements are used by more than half of all Americans, who spend more than $ 20 billion on these products each year. However, scientific evidence is insufficient in the long-term health supplements.

For the study, Neuhouser and colleagues included 161,808 women participating in the Women’s Health Initiative clinical trials: a little over 40 per cent are in trials of hormone therapy, dietary interventions and calcium and vitamin D and just under 60 per cent of them participated in the observation, the study (ie they were going about their daily lives, without intervention, and those who took multivitamins made of personal choice).

The Women’s Health Initiative is one of the largest preventive studies of the United States of its kind and aims to the most common causes of death, disability and disadvantage to the quality of life in postmenopausal women.

The researchers collected data on all participants at baseline (base) and at intervals throughout the study period. The women enrolled between 1993 and 1998 and were followed for a median of 8 years in clinical trials and 7.9 years in the observational study.

The incidence of death and disease have been recorded until 2005, including invasive breast cancer, cancers of the colon / rectum, kidney, bladder, stomach, ovary and lung. The researchers also found cases of cardiovascular diseases such as myocardial infarction (heart attack), stroke and venous thromboembolism (blood clot).